Ocera Therapeutics, Inc.
Ocera Therapeutics, Inc. (Form: SC 13D/A, Received: 02/09/2017 13:53:07)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

SCHEDULE 13D

U NDER THE S ECURITIES E XCHANGE A CT OF 1934

(Amendment No. 2)*

 

 

Ocera Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

67552 A 10 8

(CUSIP Number)

W. STEPHEN HOLMES III

INTERWEST PARTNERS

2710 SAND HILL ROAD, SUITE 200

MENLO PARK, CALIFORNIA 94025

TELEPHONE: (650) 854-8585

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 7, 2017

(Date of Event Which Requires Filing of this Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☒

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

 

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ).

 

 

 


CUSIP No. 67552 A 10 8    13D   

 

  1.   

Name of Reporting Persons

 

InterWest Partners IX, L.P.

  2.  

Check the Appropriate Box if a Member of a Group (see instructions)

(a)  ☐        (b)  ☒(1)

 

  3.  

SEC USE ONLY

 

  4.  

Source of Funds (see instructions)

 

WC

  5.  

Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

 

  6.  

Citizenship or Place of Organization

 

California, United States of America

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

 

     7.    

Sole Voting Power

 

94,762 shares of Common Stock (2)

     8.   

Shared Voting Power

 

0

     9.   

Sole Dispositive Power

 

94,762 shares of Common Stock (2)

   10.   

Shared Dispositive Power

 

0

11.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

94,762 shares of Common Stock (2)

12.  

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

 

13.  

Percent of Class Represented by Amount in Row 11

 

0.4% (3)

14.  

Type of Reporting Person (see instructions)

 

PN

 

(1) This Amendment No. 2 to Schedule 13D is filed by InterWest Partners IX, L.P. (“InterWest IX”), InterWest Management Partners IX, LLC (“IMP IX,” together with InterWest IX, the “InterWest Entities”), Philip T. Gianos (“Gianos”), W. Stephen Holmes III (“Holmes”), Gilbert H. Kliman (“Kliman”), Arnold L. Oronsky (“Oronsky”) and Khaled A. Nasr (“Nasr”). Together with the InterWest Entities, Gianos, Holmes, Kliman, Oronsky and Nasr are herein collectively referred to as the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.
(2) The shares are owned by InterWest IX and represent shares of Common Stock issuable pursuant to common stock purchase warrants. IMP IX serves as the general partner of InterWest IX. Gianos, Holmes, Kliman and Oronsky are Managing Directors of IMP IX and Nasr is a Venture Member of IMP IX and share voting and dispositive power over the shares held by InterWest IX, and may be deemed to own beneficially the shares held by InterWest IX.
(3) This percentage set forth on the cover sheets is calculated based on 23,143,938 shares of the Common Stock outstanding (as of October 31, 2016) based on the Issuer’s Form 10-Q for the quarterly period ended September 30, 2016 as filed with the Securities and Exchange Commission on November 2, 2016.

 

2.


CUSIP No. 67552 A 10 8    13D   

 

  1.   

Name of Reporting Persons

 

InterWest Management Partners IX, LLC

  2.  

Check the Appropriate Box if a Member of a Group (see instructions)

(a)  ☐        (b)  ☒(1)

 

  3.  

SEC USE ONLY

 

  4.  

Source of Funds (see instructions)

 

WC

  5.  

Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

 

  6.  

Citizenship or Place of Organization

 

California, United States of America

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

 

     7.    

Sole Voting Power

 

94,762 shares of Common Stock (2)

     8.   

Shared Voting Power

 

0

     9.   

Sole Dispositive Power

 

94,762 shares of Common Stock (2)

   10.   

Shared Dispositive Power

 

0

11.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

94,762 shares of Common Stock (2)

12.  

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

 

13.  

Percent of Class Represented by Amount in Row 11

 

0.4% (3)

14.  

Type of Reporting Person (see instructions)

 

OO

 

(1) This Amendment No. 2 to Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.
(2) The shares are owned by InterWest IX and represent shares of Common Stock issuable pursuant to common stock purchase warrants. IMP IX serves as the general partner of InterWest IX. Gianos, Holmes, Kliman and Oronsky are Managing Directors of IMP IX and Nasr is a Venture Member of IMP IX and share voting and dispositive power over the shares held by InterWest IX, and may be deemed to own beneficially the shares held by InterWest IX.
(3) This percentage set forth on the cover sheets is calculated based on 23,143,938 shares of the Common Stock outstanding (as of October 31, 2016) based on the Issuer’s Form 10-Q for the quarterly period ended September 30, 2016 as filed with the Securities and Exchange Commission on November 2, 2016.

 

3.


CUSIP No. 67552 A 10 8    13D   

 

  1.   

Name of Reporting Persons

 

Philip T. Gianos

  2.  

Check the Appropriate Box if a Member of a Group (see instructions)

(a)  ☐        (b)  ☒(1)

 

  3.  

SEC USE ONLY

 

  4.  

Source of Funds (see instructions)

 

WC

  5.  

Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

 

  6.  

Citizenship or Place of Organization

 

United States of America

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

 

     7.    

Sole Voting Power

 

0

     8.   

Shared Voting Power

 

94,762 shares of Common Stock (2)

     9.   

Sole Dispositive Power

 

0

   10.   

Shared Dispositive Power

 

94,762 shares of Common Stock (2)

11.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

94,762 shares of Common Stock (2)

12.  

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

 

13.  

Percent of Class Represented by Amount in Row 11

 

0.4% (3)

14.  

Type of Reporting Person (see instructions)

 

IN

 

(1) This Amendment No. 2 to Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.
(2) The shares are owned by InterWest IX and represent shares of Common Stock issuable pursuant to common stock purchase warrants. IMP IX serves as the general partner of InterWest IX. Gianos, Holmes, Kliman and Oronsky are Managing Directors of IMP IX and Nasr is a Venture Member of IMP IX and share voting and dispositive power over the shares held by InterWest IX, and may be deemed to own beneficially the shares held by InterWest IX.
(3) This percentage set forth on the cover sheets is calculated based on 23,143,938 shares of the Common Stock outstanding (as of October 31, 2016) based on the Issuer’s Form 10-Q for the quarterly period ended September 30, 2016 as filed with the Securities and Exchange Commission on November 2, 2016.

 

4.


CUSIP No. 67552 A 10 8    13D   

 

  1.   

Name of Reporting Persons

 

W. Stephen Holmes III

  2.  

Check the Appropriate Box if a Member of a Group (see instructions)

(a)  ☐        (b)  ☒(1)

 

  3.  

SEC USE ONLY

 

  4.  

Source of Funds (see instructions)

 

WC

  5.  

Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

 

  6.  

Citizenship or Place of Organization

 

United States of America

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

 

     7.    

Sole Voting Power

 

0

     8.   

Shared Voting Power

 

94,762 shares of Common Stock (2)

     9.   

Sole Dispositive Power

 

0

   10.   

Shared Dispositive Power

 

94,762 shares of Common Stock (2)

11.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

94,762 shares of Common Stock (2)

12.  

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

 

13.  

Percent of Class Represented by Amount in Row 11

 

0.4% (3)

14.  

Type of Reporting Person (see instructions)

 

IN

 

(1) This Amendment No. 2 to Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.
(2) The shares are owned by InterWest IX and represent shares of Common Stock issuable pursuant to common stock purchase warrants. IMP IX serves as the general partner of InterWest IX. Gianos, Holmes, Kliman and Oronsky are Managing Directors of IMP IX and Nasr is a Venture Member of IMP IX and share voting and dispositive power over the shares held by InterWest IX, and may be deemed to own beneficially the shares held by InterWest IX.
(3) This percentage set forth on the cover sheets is calculated based on 23,143,938 shares of the Common Stock outstanding (as of October 31, 2016) based on the Issuer’s Form 10-Q for the quarterly period ended September 30, 2016 as filed with the Securities and Exchange Commission on November 2, 2016.

 

5.


CUSIP No. 67552 A 10 8    13D   

 

  1.   

Name of Reporting Persons

 

Gilbert H. Kliman

  2.  

Check the Appropriate Box if a Member of a Group (see instructions)

(a)  ☐        (b)  ☒(1)

 

  3.  

SEC USE ONLY

 

  4.  

Source of Funds (see instructions)

 

WC

  5.  

Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

 

  6.  

Citizenship or Place of Organization

 

United States of America

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

 

     7.    

Sole Voting Power

 

0

     8.   

Shared Voting Power

 

94,762 shares of Common Stock (2)

     9.   

Sole Dispositive Power

 

0

   10.   

Shared Dispositive Power

 

94,762 shares of Common Stock (2)

11.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

94,762 shares of Common Stock (2)

12.  

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

 

13.  

Percent of Class Represented by Amount in Row 11

 

0.4% (3)

14.  

Type of Reporting Person (see instructions)

 

IN

 

(1) This Amendment No. 2 to Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.
(2) The shares are owned by InterWest IX and represent shares of Common Stock issuable pursuant to common stock purchase warrants. IMP IX serves as the general partner of InterWest IX. Gianos, Holmes, Kliman and Oronsky are Managing Directors of IMP IX and Nasr is a Venture Member of IMP IX and share voting and dispositive power over the shares held by InterWest IX, and may be deemed to own beneficially the shares held by InterWest IX.
(3) This percentage set forth on the cover sheets is calculated based on 23,143,938 shares of the Common Stock outstanding (as of October 31, 2016) based on the Issuer’s Form 10-Q for the quarterly period ended September 30, 2016 as filed with the Securities and Exchange Commission on November 2, 2016.

 

6.


CUSIP No. 67552 A 10 8    13D   

 

  1.   

Name of Reporting Persons

 

Arnold L. Oronsky

  2.  

Check the Appropriate Box if a Member of a Group (see instructions)

(a)  ☐        (b)  ☒(1)

 

  3.  

SEC USE ONLY

 

  4.  

Source of Funds (see instructions)

 

WC

  5.  

Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

 

  6.  

Citizenship or Place of Organization

 

United States of America

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

 

     7.    

Sole Voting Power

 

0

     8.   

Shared Voting Power

 

94,762 shares of Common Stock (2)

     9.   

Sole Dispositive Power

 

0

   10.   

Shared Dispositive Power

 

94,762 shares of Common Stock (2)

11.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

94,762 shares of Common Stock (2)

12.  

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

 

13.  

Percent of Class Represented by Amount in Row 11

 

0.4% (3)

14.  

Type of Reporting Person (see instructions)

 

IN

 

(1) This Amendment No. 2 to Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.
(2) The shares are owned by InterWest IX and represent shares of Common Stock issuable pursuant to common stock purchase warrants. IMP IX serves as the general partner of InterWest IX. Gianos, Holmes, Kliman and Oronsky are Managing Directors of IMP IX and Nasr is a Venture Member of IMP IX and share voting and dispositive power over the shares held by InterWest IX, and may be deemed to own beneficially the shares held by InterWest IX.
(3) This percentage set forth on the cover sheets is calculated based on 23,143,938 shares of the Common Stock outstanding (as of October 31, 2016) based on the Issuer’s Form 10-Q for the quarterly period ended September 30, 2016 as filed with the Securities and Exchange Commission on November 2, 2016.

 

7.


CUSIP No. 67552 A 10 8    13D   

 

  1.   

Name of Reporting Persons

 

Khaled A. Nasr

  2.  

Check the Appropriate Box if a Member of a Group (see instructions)

(a)  ☐        (b)  ☒(1)

 

  3.  

SEC USE ONLY

 

  4.  

Source of Funds (see instructions)

 

WC

  5.  

Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

 

  6.  

Citizenship or Place of Organization

 

United States of America

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

 

     7.    

Sole Voting Power

 

0

     8.   

Shared Voting Power

 

94,762 shares of Common Stock (2)

     9.   

Sole Dispositive Power

 

0

   10.   

Shared Dispositive Power

 

94,762 shares of Common Stock (2)

11.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

94,762 shares of Common Stock (2)

12.  

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

 

13.  

Percent of Class Represented by Amount in Row 11

 

0.4% (3)

14.  

Type of Reporting Person (see instructions)

 

IN

 

  (1) This Amendment No. 2 to Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.
  (2) The shares are owned by InterWest IX and represent shares of Common Stock issuable pursuant to common stock purchase warrants. IMP IX serves as the general partner of InterWest IX. Gianos, Holmes, Kliman and Oronsky are Managing Directors of IMP IX and Nasr is a Venture Member of IMP IX and share voting and dispositive power over the shares held by InterWest IX, and may be deemed to own beneficially the shares held by InterWest IX.
  (3) This percentage set forth on the cover sheets is calculated based on 23,143,938 shares of the Common Stock outstanding (as of October 31, 2016) based on the Issuer’s Form 10-Q for the quarterly period ended September 30, 2016 as filed with the Securities and Exchange Commission on November 2, 2016.

 

 

8.


Introductory Note :

This Amendment No. 2 (the “Amendment”) to the statement on Schedule 13D is being filed by the Reporting Persons (as defined below) and amends the Schedule 13D filed with the Securities and Exchange Commission on July 30, 2013 (the “Original Schedule 13D”) in respect of Common Stock (as defined below) of the Issuer (as defined below). This Amendment is being filed by the Reporting Persons to report the disposition of shares of Common Stock on February 7, 2017 and February 8, 2017. Accordingly, the number of securities beneficially owned by the Reporting Persons has decreased as described in Items 4 and 5 below.

Items 4 and 5 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.

Item 4. Purpose of Transaction

Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following paragraph at the end of Item 4:

On February 7, 2017, the Reporting Persons sold an aggregate of 872,759 shares of Common Stock in an open market transaction.

On February 8, 2017, the Reporting Persons sold an aggregate of 375,305 shares of Common Stock in an open market transaction.

Item 5. Interest in Securities of the Issuer

Item 5 of the Original Schedule 13D is hereby amended and restated in its entirety as follows:

The following information with respect to the ownership of the Common Stock of the Issuer by the Reporting Persons filing this Statement on Schedule 13D is provided as of the date of this filing:

 

Reporting Persons    Common
Stock Issuable
Upon Exercise
of Common
Stock
Purchase
Warrants
    

Shares

Held

Directly (1)

    

Sole

Voting

Power (1)

    

Shared

Voting

Power (1)

    

Sole

Dispositive

Power (1)

    

Shared

Dispositive

Power (1)

    

Beneficial

Ownership (1)

     Beneficial
Ownership
Percentage
of
Common
Stock (1, 3)
 

InterWest IX

     94,762         0         94,762         0         94,762         0         94,762         0.4

IMP IX (2)

     0         0         94,762         0         94,762         0         94,762         0.4

Gianos (2)

     0         0         0         94,762         0         94,762         94,762         0.4

Holmes (2)

     0         0         0         94,762         0         94,762         94,762         0.4

Kliman (2)

     0         0         0         94,762         0         94,762         94,762         0.4

Oronsky (2)

     0         0         0         94,762         0         94,762         94,762         0.4

Nasr (2)

     0         0         0         94,762         0         94,762         94,762         0.4

 

(1) Represents the number of shares of Common Stock currently underlying all Securities held by the Reporting Persons.
(2) IMP IX serves as the general partner of InterWest IX. Gianos, Holmes, Kliman and Oronsky are Managing Directors of IMP IX and Nasr is a Venture Member of IMP IX and share voting and dispositive power over the shares held by InterWest IX, and may be deemed to own beneficially the shares held by InterWest IX. Gianos, Holmes, Kliman, Oronsky and Nasr own no securities of the Issuer directly as of the date of this filing.
(3) This percentage set forth on the cover sheets is calculated based on 23,143,938 shares of the Common Stock outstanding (as of October 31, 2016) based on the Issuer’s Form 10-Q for the quarterly period ended September 30, 2016 as filed with the Securities and Exchange Commission on November 2, 2016.

 

Item 5(c). On February 7, 2017, the Reporting Persons sold an aggregate of 872,759 shares of Common Stock in an open market transaction at an average price of $0.562606 per share.

On February 8, 2017, the Reporting Persons sold an aggregate of 375,305 shares of Common Stock in an open market transaction at an average price of $0.591739 per share.

 

Item 5(d). Not applicable.

 

9.


Item 5(e). As of February 7, 2017, the Reporting Persons ceased to be beneficial owners of more than 5% of the issued and outstanding Common Stock of the Issuer. The reporting obligations of the Reporting Persons with respect to the Common Stock pursuant to Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder are therefore terminated.

 

Item 7. Material to Be Filed as Exhibits

 

A. Agreement regarding filing of joint Schedule 13D.

 

10.


SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date:    February 9, 2017

I NTER W EST P ARTNERS IX, L.P.

 

By:   InterWest Management Partners IX, LLC
Its:   General Partner
By:  

/s/ Gilbert H. Kliman

  G ILBERT H. K LIMAN
  Managing Director
I NTER W EST M ANAGEMENT P ARTNERS IX, LLC
By:  

/s/ Gilbert H. Kliman

  G ILBERT H. K LIMAN
  Managing Director
 

 

/s/ Karen A. Wilson

Karen A. Wilson, Attorney-in-Fact for Philip T. Gianos

/s/ Karen A. Wilson

Karen A. Wilson, Attorney-in-Fact for W. Stephen Holmes III

/s/ Karen A. Wilson

Karen A. Wilson, Attorney-in-Fact for Gilbert H. Kliman

/s/ Karen A. Wilson

Karen A. Wilson, Attorney-in-Fact for Arnold L. Oronsky

/s/ Karen A. Wilson

Karen A. Wilson, Attorney-in-Fact for Khaled A. Nasr

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Attention: Intentional misstatements or omissions of fact

constitute Federal criminal violations (See 18 U.S.C. 1001)

 

11.


SCHEDULE I

Managers:

Philip T. Gianos

c/o InterWest Partners

2710 Sand Hill Road, Suite 200

Menlo Park, California 94025

Principal Occupation: Managing Director of IMP IX, which serves as the general partner of InterWest IX

Citizenship: United States of America

W. Stephen Holmes III

c/o InterWest Partners

2710 Sand Hill Road, Suite 200

Menlo Park, California 94025

Principal Occupation: Managing Director of IMP IX, which serves as the general partner of InterWest IX

Citizenship: United States of America

Gilbert H. Kliman

c/o InterWest Partners

2710 Sand Hill Road, Suite 200

Menlo Park, California 94025

Principal Occupation: Managing Director of IMP IX, which serves as the general partner of InterWest IX

Citizenship: United States of America

Arnold L. Oronsky

c/o InterWest Partners

2710 Sand Hill Road, Suite 200

Menlo Park, California 94025

Principal Occupation: Managing Director of IMP IX, which serves as the general partner of InterWest IX

Citizenship: United States of America

Venture Members:

Khaled A. Nasr

c/o InterWest Partners

2710 Sand Hill Road, Suite 200

Menlo Park, California 94025

Principal Occupation: Venture Member of IMP IX, which serves as the general partner of InterWest IX

Citizenship: United States of America

 

12.


EXHIBIT INDEX

 

A. Agreement regarding filing of joint Schedule 13D.

 

13.

Exhibit A

JOINT FILING STATEMENT

I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the Common Stock of Ocera Therapeutics, Inc. is filed on behalf of each of the undersigned.

 

Date:   February 9, 2017
I NTER W EST P ARTNERS IX, L.P.
By:   InterWest Management Partners IX, LLC
Its:   General Partner
By:  

/s/ Gilbert H. Kliman

  G ILBERT H. K LIMAN
  Managing Director
I NTER W EST M ANAGEMENT P ARTNERS IX, LLC
By:  

/s/ Gilbert H. Kliman

  G ILBERT H. K LIMAN
  Managing Director

 

/s/ Karen A. Wilson

Karen A. Wilson, Attorney-in-Fact for Philip T. Gianos

/s/ Karen A. Wilson

Karen A. Wilson, Attorney-in-Fact for W. Stephen Holmes III

/s/ Karen A. Wilson

Karen A. Wilson, Attorney-in-Fact for Gilbert H. Kliman

/s/ Karen A. Wilson

Karen A. Wilson, Attorney-in-Fact for Arnold L. Oronsky

/s/ Karen A. Wilson

Karen A. Wilson, Attorney-in-Fact for Khaled A. Nasr